On November 5, 2026, C4 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
|
C4 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines based on targeted protein degradation (TPD) science. The company utilizes its proprietary TORPEDO platform to design and optimize protein degraders that modulate clinically validated disease pathways. Its clinical pipeline includes cemsidomide, an orally bioavailable IKZF1 and IKZF3 degrader for multiple myeloma, and CFT8919, an EGFR L8519 degrader for non-small-cell lung cancer. C4 Therapeutics is advancing cemsidomide in Phase 1 and Phase 2 trials, including the MOMENTUM study, and is evaluating a Phase 1b trial in combination with elranatamab. The company is also expanding its discovery pipeline into inflammation, neuroinflammation, and neurodegeneration, with a focus on developing central nervous system-penetrant degraders. Strategic collaborations with Merck KGaA and Roche support the identification and development of novel degraders across multiple therapeutic areas. Betta Pharma is conducting clinical development of CFT8919 in Greater China. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Biotechnology | Homepage c4therapeutics.com |
| Sector Healthcare | IR page ir.c4therapeutics.com | |
|
Tags
targeted protein degradation, oncology, multiple myeloma, non-small-cell lung cancer, neurodegeneration, neuroinflammation, small-molecule medicines, molecular glue degraders, blood-brain barrier penetration, clinical-stage, TORPEDO, cemsidomide, CFT8919, MOMENTUM, ELREXFIO, Merck KGaA, Roche, Betta Pharma
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 356.045M |
| Market cap (USD) | $ 356.045M |
| P/E | -4.30 |
| PEG | — |
| P/BV | 1.56 |
| P/S | 11.03 |
| P/OCF | -4.47 |
| P/FCF | -3.59 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -44.4% |
| ROI | -44.6% |
| ROIC | -36.7% |
| Profit margin | -292.1% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 33 |
| Quality score | -43.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||
| Trade receivables (USD) | — | 4.62M | 4.48M | 5.72M | 1.47M | 11.8M | 3.1M | 2.4M |
| ↳ YoY growth | -3.0% | +27.5% | -74.2% | +701.0% | -73.7% | -22.6% | ||
| ↳ 5y CAGR | -7.7% | -11.7% | ||||||
| Borrowings, current (USD) | — | — | — | 0.00 | 2.29M | 0.00 | — | — |
| Borrowings, non-current (USD) | — | — | 10.1M | 10.8M | 9.2M | 0.00 | — | — |
| Lease liabilities (USD) | — | 13.7M | 12.9M | 32.1M | 75.7M | 71M | 65.8M | 60M |
| Cash and deposits (USD) | 38.9M | 90.5M | 182M | 76.1M | 29.8M | 127M | 55.5M | 74.6M |
| Right-of-use assets (USD) | — | 14.5M | 13.2M | 31.9M | 70.1M | 64M | 57.5M | 40.5M |
| Net debt (borrowings + leases - cash) (USD) | — | — | -159M | -33.2M | 57.4M | -55.6M | — | — |
| Cash flow detail | ||||||||
| Operating cash flow (USD) | — | 55.6M | -67.2M | -87M | -106M | -107M | -65.2M | -98.7M |
| Purchases of property, plant and equipment (USD) | — | -1.35M | -650,000 | -1.28M | -5.5M | -1.71M | -180,000 | -607,000 |
| Change in receivables (cash effect) (USD) | — | 81.8M | 139,000 | -1.23M | 4.24M | -10.3M | 8.7M | 701,000 |
| Change in payables (cash effect) (USD) | — | 4.23M | 467,000 | -1.18M | -3.33M | 273,000 | -119,000 | -468,000 |
| Share buybacks (cash effect) (USD) | — | -30,000 | -194,000 | — | 0.00 | -110,000 | -194,000 | -193,000 |
| Interest paid (cash effect) (USD) | — | — | -820,000 | -1.31M | -1.62M | -990,000 | 0.00 | — |
| Income taxes paid (cash effect) (USD) | — | -1.09M | -143,000 | — | 0.00 | -1M | 0.00 | -131,000 |
| Share-based compensation (USD) | — | 1.64M | 3.43M | 21.5M | 30M | 27.2M | 29.7M | 19.1M |
| Operating cash flow before change in receivables (USD) | — | -26.2M | -67.4M | -85.7M | -110M | -96.5M | -73.9M | -99.4M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | 54.3M | -67.9M | -88.2M | -111M | -109M | -65.3M | -99.3M |
| Income detail | ||||||||
| Research and development expense (USD) | — | 48.1M | 78.4M | 94.7M | 118M | 118M | 111M | 104M |
| ↳ 5y CAGR | +18.1% | +5.9% | ||||||
| Total comprehensive income (USD) | — | -34.1M | -66.3M | -84.7M | -132M | -128M | -105M | -105M |
| Comprehensive income to owners (USD) | — | -34.1M | -66.3M | -84.7M | -132M | -128M | -105M | -105M |
| Reported | Nov 12, 2020 | Mar 11, 2021 | Mar 11, 2021 | Aug 4, 2022 | Feb 22, 2024 | Feb 22, 2024 | Feb 27, 2025 | Feb 26, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
October 29, 2026
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage
WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today highlighted its novel DNA-encoded library (DEL) that leverages C4T’s large library of cereblon-binding ligands and screening capabilities in a presentation at the 9th Annual Targeted Protein Degradation Summit in Boston titled “Target-First Discovery of Molecular Glue Degraders Using DNA-Encoded Libraries.”
“Our new DEL capability captures both our strong track record of investing in cereblon and driving innovation across targeted protein degradation science to create a differentiated engine for generating new drug discovery opportunities,” said Scott Boyle, chief business officer of C4 Therapeutics. “To date, this new technology has shown it can deliver attractive hits against high-value targets within four months and further enhances the speed and precision of our discovery efforts. We are eager to push the boundaries of this library and our rapid screening process with diverse and undruggable targets both for our own internal pipeline and alongside future partners.”
Integrated within C4T’s TORPEDO® platform, the addition of DEL creates a powerful hit-finding engine that enables the rapid development of targeted protein degraders. C4T has integrated the company’s cereblon-binding ligand libraries into its DEL capability, which has helped develop a diverse library unique to C4T. The target-first approach integrated into C4T’s DEL technology further enables rapid evaluation, validation, characterization and development of molecular glue degraders.
C4T has validated this DEL capability by identifying both known and novel molecular glue degrader hits for VAV1, which C4T does not plan to advance without a partner. Led by its target-first approach, C4T has also screened a range of high-value targets where degradation turns undruggable to druggable or provides a therapeutic benefit relative to inhibitors; this has identified hits for additional undisclosed targets. C4T remains focused on advancing cemsidomide through clinical development and its discovery strategy centered around undisclosed targets that drive inflammation, neuroinflammation and neurodegenerative diseases.
C4T will highlight this new capability and more information on the VAV1 target in a presentation at the 9th Annual Targeted Protein Degradation Summit on October 29, 2026. The presentation is available on C4T’s website, under Scientific Presentations and Publications.
About the TORPEDO**®**Platform The proprietary TORPEDO® platform drives C4 Therapeutics’ (C4T) efforts to create a new generation of small molecule medicines centered around heterobivalent degraders (BiDAC™ degraders), molecular glue degraders (MonoDAC® degraders) and degrader-antibody conjugates (DACs). A DNA-encoded library (DEL) that leverages C4T’s cereblon binder library alongside machine learning and artificial intelligence serves as a rapid hit-finding engine. Once a hit is identified, the TORPEDO platform utilizes diverse chemical libraries, degrader design assisted by structural biology, ternary complex models and proteomics, allowing C4T’s scientists to rapidly design degraders with properties that enhance catalytic degradation turnover and drug performance that directly impact disease.
About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Forward Looking Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to discover or develop potential therapies for patients; the capabilities and potential benefits of our DEL and its ability to accelerate drug discovery; the capabilities of the TORPEDO® platform; the advancement, timing, progress and potential benefits of our discovery and clinical programs, including cemsidomide; the potential for future collaborations, partnerships, milestone or royalty payments; and our ability to fund its future operations. Any forward-looking statements in this press release are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks inherent in drug discovery and development; the risk that screening results or identified hits may not be reproducible, validated or successfully translated into product candidates; the risk that the results of preclinical studies and/or clinical trials will not be predictive of results from future studies or trials; the timing and outcome of regulatory submissions or interactions; and the risk that any one or more of our programs or product candidates will cost more to develop or may not be successfully developed and commercialized. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.
September 25, 2026
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action
Biomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elranatamab Reinforce Cemsidomide’s Ability to Drive T-cell Expansion and Activation, and Prevent T-cell Exhaustion When Combined with Immune-based Therapies
First Cemsidomide Dose Level (75 µg) in Phase 1b Trial with Elranatamab Declared Safe by Safety Data Review Committee; Advancing Trial to Dose Expansion and Escalation Cohorts with Data from All Cohorts Evaluated Expected in Mid-2027
WATERTOWN, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, presented new biomarker data today from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) in a poster presentation at the 23rd IMS Annual Meeting. In addition, the poster included preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of cemsidomide in combination with elranatamab (ELREXFIO®). These data further build upon the body of evidence supporting cemsidomide's immunomodulatory activity and potential as a combination partner.
“Immune-based therapies have transformed the treatment landscape for multiple myeloma, however T-cell exhaustion is associated with both primary resistance and relapse in these patients. Maintaining T-cell fitness is an important component of achieving deep and durable responses,” said Len Reyno, M.D., chief medical officer of C4 Therapeutics. “The totality of data presented today demonstrate that cemsidomide activates immune cell function, consistent with the hypothesis that cemsidomide will enhance the clinical benefit of immune-based therapies when used in combination. Additionally, clearing the 75 µg cemsidomide dose level in our Phase 1b trial is a critical step forward in identifying an effective and safe dose of cemsidomide in combination with a BCMA-directed T-cell engager, like elranatamab. Collectively, these outcomes, along with the differentiated safety profile and compelling anti-myeloma activity observed in our Phase 1 trial, reinforce our development strategy to potentially establish cemsidomide as a backbone therapy in multiple myeloma for patients in need of new treatment options.”
IMS Data Highlights and Cemsidomide Trial Progress Update:
Phase 1 Trial of Cemsidomide in Combination with Dexamethasone In 62 heavily pre-treated RRMM patients across the once-daily (QD) dose levels, cemsidomide demonstrated coordinated activation of T cells, including CD8+ T cells, and functional reprogramming of natural killer (NK) cells. Notably, enhanced immune cell function was observed at the highest dose levels studied (75 µg and 100 µg), which also achieved compelling overall response rates in the Phase 1 trial.
Phase 1b Trial of Cemsidomide in Combination with Elranatamab Biomarker data from the first two patients showed that cemsidomide drives the expansion and activation of CD8+ effector memory T cells as measured by elevated HLA-DR and prevents T-cell exhaustion as measured by PD-1, TIM-3 and LAG3 expression.(1) These initial findings provide positive translational and mechanistic support for cemsidomide as a potential combination partner for immune-based therapies.
In addition, following the completion of the first safety cohort evaluating six patients, the safety data review committee declared the 75 µg cemsidomide dose level in combination with elranatamab safe. The Phase 1b trial is now advancing into a dose escalation safety cohort at the 100 µg cemsidomide dose level and an expansion cohort at the 75 µg cemsidomide dose level. Data from all cohorts evaluated in the Phase 1b trial are expected in mid-2027.
About Cemsidomide Cemsidomide is an investigational oral cereblon-modulating protein degrader of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the fully enrolled Phase 1 trial show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that supports the potential for durable outcomes.
About Cemsidomide in Combination with Elranatamab (ELREXFIO®) The Phase 1b trial is designed to evaluate the safety, tolerability and preliminary efficacy of cemsidomide and dexamethasone in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. Data generated from the cemsidomide Phase 1 trial in relapsed/refractory multiple myeloma demonstrate robust T-cell activation and cytokine expression across multiple doses. By activating immune T-cells, cemsidomide, when combined with a BCMAxCD3 bispecific such as elranatamab, may amplify the anti-myeloma immune response and lead to deeper and more durable responses. The study will evaluate different cemsidomide dose levels (beginning with 75 µg, with the opportunity to simultaneously explore 50 µg and 100 µg) in patients who have received one to four prior lines of therapy, which must have consisted of at least one IKZF1/3 degrader. Exclusion criteria for patients include those who have received prior treatment with a BCMA-directed T-cell engager or BCMA-directed CAR-T therapy. More information is available at clinicaltrials.gov (NCT07280013).
About Multiple Myeloma Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow. It is the second most common blood cancer, with approximately 36,000 people in the United States diagnosed each year. Multiple myeloma is characterized by cycles of remission and relapse, which leads to patients needing multiple lines of therapy to manage the persistent disease. More than 175,000 patients in the United States are estimated to be living with or in remission from myeloma. However, despite treatment advances, approximately 40% of patients do not survive beyond five years.
About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Forward Looking Statement This press release contains “forward-looking statements” of C4 Therapeutics, Inc., within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding the clinical significance of the biomarker data presented from the Company’s Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with RRMM and the Phase 1b trial of cemsidomide in combination with elranatamab; the ability of cemsidomide to drive coordinated activation of T cells and functional reprogramming of NK cells; the potential of enhanced immune cell function observed at the highest dose levels studied to translate into clinical benefit; the ability of cemsidomide to drive the expansion and activation of CD8+ effector memory T cells and prevent T-cell exhaustion; the translational and mechanistic support for cemsidomide as a potential combination partner for immune-based therapies; the advancement of the Phase 1b trial into a dose escalation safety cohort at the 100 µg cemsidomide dose level and an expansion cohort at the 75 µg cemsidomide dose level; the anticipated timing of data from all cohorts evaluated in the Phase 1b trial in mid-2027; and the design and potential efficacy of the Company’s therapeutic approaches. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for the Company’s product candidates; the risk that preclinical or clinical data, including biomarker data or signs of biologic activity, may not be predictive of long-term results or translate across programs or the patient population; the risk that any one or more of the Company’s product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund the Company’s future operations will be available to the Company on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. Except as otherwise noted, the information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.
(1) Based on available biomarker data, as of June 22, 2026, from the first two patients to complete Cycle 1.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding C4 Therapeutics, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| VFMO | 0.08% | 402,767 | $ 1.494M | Aug 31, 2026 |
| FESM | 0.06% | 780,673 | $ 3.646M | Jun 30, 2026 |
| AVSC | 0.02% | 207,075 | $ 548.749K | Nov 16, 2026 |
| RESM | 0.02% | 118 | $ 551.06 | Jun 30, 2026 |
| DFAS | 0.00% | 452,372 | $ 1.253M | Nov 12, 2026 |
| DXUV | 0.00% | 47,153 | $ 130.614K | Nov 12, 2026 |
| DFAC | 0.00% | 316,636 | $ 877.082K | Nov 12, 2026 |
| DFSU | 0.00% | 8,504 | $ 23.556K | Nov 12, 2026 |
| DCOR | 0.00% | 135,387 | $ 375.022K | Nov 12, 2026 |
| DFAU | 0.00% | 35,029 | $ 97.03K | Nov 12, 2026 |
| DFUS | 0.00% | 26,079 | $ 72.239K | Nov 12, 2026 |